New chemo cocktail shows promise in shrinking breast tumors before surgery
NCT ID NCT00295893
First seen Oct 31, 2025 · Last updated May 15, 2026 · Updated 26 times
Summary
This study tested two different chemotherapy regimens given before surgery to shrink tumors in people with stage II or III breast cancer. One group received a standard three-drug combo (TAC), while the other received two different combos in sequence (ACAC), with some also getting trastuzumab if their cancer was HER2-positive. The goal was to see which approach led to no cancer remaining in the breast or lymph nodes at surgery. The trial enrolled 121 participants and is now complete but not actively recruiting.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
City of Hope Medical Center
Duarte, California, 91010-3000, United States
Conditions
Explore the condition pages connected to this study.